Kenvue Inc KVUE

$17.20 -0.02 (-0.12%)

Valuation

Market cap
33,075,728,000
Revenue TTM
$15,124,000,000
Net income TTM
$1,470,000,000
PE ratio
14.97
Forward PE
15.46
Profit margin
9.72%
Debt to equity
0.67

Trading

Volume
13,996,700
Avg volume
23,253,527
Day's range
$17.16 – $17.38
Shares out
1,920,774,000
Stochastic %K
4%
Beta
0.48
Analysts
Sell
Price target
$19.25

Price

Company profile

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally insp...

Show more

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Industry
Household & Personal Products
Sector
Consumer Defensive
Phone
908 874 1200
Website
https://www.kenvue.com
Address
1 Kenvue Way, Summit, United States

Latest news

Stocktwits

thatsolardude365 Oct 3, 11:08 AM
$KVUE holders: open class action over alleged face-geometry scans from Neutrogena's Skin360 app. $4.7M settlement, no proof needed to file, claim by Nov 25. Details on Open Class Actions.
0 replies
InfinitelyStoned Oct 2, 1:49 PM
$KVUE I obviously did not get the memo about the early dividend. I assume this has something to do with the sale of the company to Kimberly Clark?
0 replies
Cubsfan201 Oct 2, 12:45 PM
$KVUE As of yesterdays close, the buyout is below current share price. How sad is that?
0 replies
prismmarketview Sep 30, 2:20 PM
$KVUE Kenvue to present 12 new scientific data sets across Neutrogena, Aveeno, Regaine at EADV 2026 (Vienna). Neutrogena: small Brazilian studies (oily/acne-prone skin) showed 56% less visible redness, 46% less hyperpigmentation, up to 12% less oiliness after 28 days; separate dry-skin study showed 22% hydration improvement. Aveeno: Triple Oat Complex research showed barrier/hydration/ceramide gains; survey of 178 dermatologists found 87.6% frequently recommend a colloidal oat emollient alongside steroids for eczema (survey data, not a controlled trial). Regaine: post-hoc Phase 3 analysis, men 20-30 gained avg 26.25 non-vellus hairs vs 19.93 for 30+; earlier-stage (Type III) hair loss gained more than advanced (Type IV/V). Post-hoc = pattern, not proof for every patient. No sales/earnings forecast tied to any of this. R&D-driven brand positioning, not a financial catalyst. $KVUE #ConsumerHealth #Skincare https://prismmarketview.com/kenvue-highlights-new-neutrogena-aveeno-and-regaine-research-at-eadv-2026/
0 replies
OnlyFibs Sep 30, 1:39 AM
$KVUE | Snapshot 📊⚡ • Business: Kenvue Inc. is the world’s largest pure-play consumer health company, operating high-margin brands in self-care, skin health, and essential wellness. • Financial Health & Pipeline: Stable defensive dividend yield with reliable free cash flow, capitalizing on steady global consumer demand across retail health categories. • Bias & Conviction: Bullish Channel Reversal | Moderate Conviction (Holding structural trendline support at $17.30 backed by 2027 call LEAPS sweep flow). 🎯 Key Levels: 🐂 Bull Trigger: $17.50 / $17.91 🚀 Targets: $19.50 / $21.00 / $22.00 🛡️ Support: $17.30 / $17.10 ⚠️ Risk: $15.00 / $14.00 🔥 Volume & Flow: • 🟢 Bullish long-term flow featuring $87.5K in 12/17/2027 $15C and $26.3K in 12/17/2027 $18C sweeps hitting the ask. #KVUE #consumerhealth #stocks #finance #hovdid
0 replies
SuperGreenToday Sep 26, 12:43 AM
$KVUE Share Price: $17.82 Contract Selected: Oct 23, 2026 $20 Calls Buy Zone: $0.07 – $0.09 Target Zone: $0.12 – $0.14 Potential Upside: 61% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
TalkMarkets Sep 23, 4:08 PM
Burning A Hole In My Pocket $VICI $KMB $CZR $KVUE https://talkmarkets.com/article/burning-a-hole-in-my-pocket
0 replies
peloswing Sep 22, 4:08 PM
$KVUE catching a bid off its 50 DMA and about to retest this diagonal trendline. Will look good if it can get back inside the triangle.
0 replies